Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Biocytogen Sells Option for HER2/TROP2 Bispecific ADC to Radiance Biopharma

publication date: Jan 8, 2024

Beijing Biocytogen Pharma sold an option for a first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate to Radiance Biopharma of Boston. If Radiance exercises the option, it will have rights to the bispecific ADC for all human indications worldwide. HER2 and TROP2 are two tumor-associated antigens commonly expressed in multiple solid tumor cancers. Biocytogen will be entitled to receive option and licensing fees, milestone payments and single-digit royalties on net sales. It will also receive a share of any sublicensing fee. Biocytogen applies its gene editing technology to create animal models for antibody drug discovery. More details....

Stock Symbols: (HK: 02315)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here